BioSpace News Archive

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today announced that it is advancing the research and development of an artificial intelligence (AI) medical device platform in collaboration with technical advisory partner Reified Labs.

Inozyme Pharma, Inc. today announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency.

NorthStar Medical Radioisotopes, LLC, and Nucleus RadioPharma announced the signing of a supply agreement for the therapeutic radioisotope actinium-225.

SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health.

ValGenesis, Inc. announced that a global biotechnology company selected ValGenesis VLMS to digitize the computer system validation and equipment qualification processes across the organization after a rigorous audit of possible solutions.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces the next commercialization stage of its proBEAT™ sensor and AI-based feedback platform, augmenting the BEAT™diabetes program.

IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase I clinical trial in the U.S.

Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage,

Dr. Brian Cornblatt will give the keynote address on the “HealthConf” Stage at Collision